PDT/PDD research
Photosensitizer
Radachlorin
Next-generation photosensitizer drugs that are licensed and sold in Russia and Korea as a wide range of medicine.
라다클로린(Radachlorin®)
- The maximum absorption wavelength is 662nm, which is more deep than 630nm, so it is effective for treating solid cancer
- The accumulation ratio of cancer cells to normal tissue is 3 to 30 times higher, which is excellent for antiseptic specificity
- The PDT treatment is performed within 3-5 hours of intravenous injection, so it should be treated after the injection on the same day
- 98% of the drug is excreted in 2 days, so photosensitivity will be resolved within 5-6 days
- It is a next-generation photosensitizer drugs that are licensed and sold in Russia and Korea as a wide range of medicine
Product Information
| Product Name | 라다클로린(Radachlorin®) |
|---|---|
| ngredients / Contents | 5mg/10mL of Sodium Chloride in Chlorine e6 |
| Category / Code | Specialty rare drugs / other tumor treatment (04290) |
| Date of permission | 2008. 12. 17. |
| Appearance | a dark-green liquid with a yellowish color and unusual odor |
| Effectiveness | Wide dynamic treatment of skin base cell cancer where other treatments, such as surgery except melanoma, are inappropriate. |
| Dosage | The optimal treatment capacity is 1.0-1.2 mg/kg and irradiates a wavelength of 662 ± 3 nm, 200 or 300 J/cm2. (In the case of stage T1-2N0M0 skin base cell cancer patients, a dose of 0.5-0.6 mg/kg is examined for 300 J/cm2 of light after drug administration.) This drug was injected over a period of 30 minutes with a spot injection.The 662 ± 3 nm light irradiation shall begin three hours after the injection of the drug. * Preparation of an intravenous solution: Dilute it to 200mL using the following solution.Do not use intravenous infusion solutions containing acidic drugs (e.g., ascorbic acid). -0.9 percent sodium chloride, 5% dextrose, 10% dextrose, 10% mannitol, ringer liquid, 4% potassium chloride, 8% potassium chloride |
| Package Unit | 1vial/box |
